Publications

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.

Zhou J. et al, (2023), Pharmacoeconomics

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Humbert M. et al, (2023), European Respiratory Journal, 61

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.

Gaziano L. et al, (2022), Circulation

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.

Staplin N. et al, (2022), Hypertension

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.

Pitcher A. et al, (2022), Lancet

CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.

Kotecha D. et al, (2022), Lancet Digit Health

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Focused cardiac ultrasound to guide the diagnosis of heart failure in pregnant women in India.

Alsharqi M. et al, (2022), J Am Soc Echocardiogr

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.

Task Force for the management of COVID-19 of the European Society of Cardiology None. et al, (2022), Cardiovascular research, 118, 1385 - 1412

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.

Task Force for the management of COVID-19 of the European Society of Cardiology None., (2022), European heart journal, 43, 1059 - 1103

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.

Task Force for the management of COVID-19 of the European Society of Cardiology None., (2022), European heart journal, 43, 1033 - 1058

Cookies on this website

Publications